LAUREN BELOVE: Open Payments
NPI 1245831338 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,470 in 19 payments from 8 companies in 2025. Trend: 2023 $1,115 · 2024 $2,116 · 2025 $1,470
Food & beverage: $1,455Education: $15
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $391 |
| GENZYME CORPORATION | 4 | $295 |
| EMD Serono, Inc. | 2 | $234 |
| ARGENX US, INC. | 2 | $151 |
| UCB, Inc. | 2 | $140 |
| ABBVIE INC. | 1 | $125 |
| ACADIA Pharmaceuticals Inc | 1 | $115 |
| PFIZER INC. | 1 | $18 |
Products named: KESIMPTA, VYVGART, QULIPTA, Nayzilam, Mavenclad, NUPLAZID, VYVGART HYTRULO, NURTEC ODT.
Industry payments across NV — which companies pay providers there.
